GLP-1 Drugs Turn Out to Have a Lot More to Say About Cancer
Two separate research teams published findings about GLP-1 drugs on the same day, and together they paint a more complex picture of these medications than most people carry.
First: a Stanford Medicine study found that roughly 10% of people carry genetic variants that make them far less responsive to Ozempic and similar diabetes drugs, a phenomenon the researchers call "GLP-1 resistance." These individuals actually produce higher-than-normal levels of GLP-1 naturally, but the hormone does not work effectively in their bodies, and they were significantly less likely to reach blood sugar targets after six months of treatment [6]. Second and separately: a University of Pennsylvania study of more than 110,000 women found that those on GLP-1 medications had about 30% lower likelihood of developing breast cancer [11]. Clinical trials are now being planned to test that finding directly.
Scientists discover why ozempic may not work for some people
The Stanford research shows that not all patients are equal when facing these drugs, which has direct implications for precision medicine in diabetes care. If doctors could screen for these genetic variants in advance, they could route patients toward the treatment most likely to help them rather than waiting six months to discover a drug is not working [6]. The researchers explicitly frame this as a step toward personalized diabetes care, and they note that the roughly 10% of the population carrying these variants represents a substantial number of people currently on a medication that is not benefiting them.
Read the storyOzempic and similar weight-loss drugs linked to 30% lower breast cancer risk
The Penn research is observational, which means it cannot yet prove cause and effect, and the researchers are careful about that. But a 30% reduction in breast cancer incidence across 110,000 women is a signal strong enough to justify the prospective clinical trial they are now planning. The leading hypothesis is that GLP-1 drugs reduce cancer risk at least partly through weight loss, but researchers are not certain that weight alone explains the effect [11]. The coverage missed almost entirely the question of what these two findings together suggest about population-level screening: if one in ten people is genetically resistant to GLP-1 drugs for diabetes while a separate cohort benefits from significant cancer risk reduction, the optimization questions around who gets prescribed these drugs become considerably more complicated.
Read the story




